{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.3","upperLimit":"8.1","value":"-0.48"},{"groupId":"OG001","lowerLimit":"-2.3","upperLimit":"9.6","value":"-0.69"},{"groupId":"OG002","lowerLimit":"-2.3","upperLimit":"8.3","value":"-1.11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"63"},{"groupId":"OG002","value":"52"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.3","upperLimit":"8.1","value":"-0.04"},{"groupId":"OG001","lowerLimit":"-2.3","upperLimit":"7.5","value":"-0.89"},{"groupId":"OG002","lowerLimit":"-2.3","upperLimit":"10.1","value":"-0.51"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"63"},{"groupId":"OG002","value":"48"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"End of Core Phase"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.5","upperLimit":"1.6","value":"0.00"},{"groupId":"OG001","lowerLimit":"-10.0","upperLimit":"2.1","value":"0.00"},{"groupId":"OG002","lowerLimit":"-3.3","upperLimit":"1.7","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"46"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Change from Baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"94"},{"groupId":"OG002","value":"85"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"The brief version of the WNV consists of a 2-subtest battery: only Matrices and Recognition subtests for patients under 8, and Matrices and Spatial Span subtests for patients aged 8 to 21. Based on the raw scores obtained from the subtests, standardized z-scores were calculated for each subtest using the following formula: Zscore = (X - b)/Sb where X is the raw score of the subtest, b and Sb represent the mean and standard deviation respectively of the subtest score recorded at baseline for the study population. The composite WNV score was computed by summing up the Z-scores of the 3 subtests of the WNV (i.e. matrices, recognition, and coding for patients aged \\<8 years and matrices, spatial span, and coding for patients aged 8 to 21 years). The composite WNV score has no range.","dispersionType":"Full Range","groups":[{"description":"Participants were randomized to receive everolimus dispersible tablets for oral suspension with titration to a low trough (LT) range of 3 to 7 ng/mL","id":"OG000","title":"Everolimus LT Target of 3 to 7 ng/mL"},{"description":"Participants were randomized to receive everolimus dispersible tablets for oral suspension with titration to a high trough (HT) range of 9 to 15 ng/mL","id":"OG001","title":"Everolimus HT Target of 9 to 15 ng/mL"},{"description":"Participants were randomized to receive placebo dispersible tablets for oral suspension.","id":"OG002","title":"Placebo"},{"description":"Participants who were treated with everolimus either in the Core or Extension phases of the study and were evaluated for longer term safety and efficacy.","id":"OG003","title":"Everolimus Long Term Evaluation (LTE)"}],"paramType":"MEDIAN","populationDescription":"The safety Set comprised all patients who received at least one dose of study treatment and had at least one post-baseline safety assessment in the Core phase (where the statement that a patient had no AE constitutes a safety assessment.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 18","title":"Core Phase: Change From Baseline in Wechsler Nonverbal Composite Score","type":"SECONDARY","unitOfMeasure":"scores on a scale"}